SBRT 2016

SBRT for stage I NSCLC

100%

All cancer

13%

Lung cancer

(13%)

10.4%

NSCLC

(80%)

2.1%

Early stage NSCLC

(20%)

0.23%

Inoperable stage I NSCLC

(11%)

 Stage I NSCLC = RARE DISEASE  Majority of our patient will NOT benefit from SBRT  Proof of principle

ESTRO SBRT COURSE 2016 - Matthias Guckenberger

4

/